Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
81,183,875
-
Shares change
-
-15,624,829
-
Total reported value, excl. options
-
$58,271,372
-
Value change
-
-$32,826,439
-
Put/Call ratio
-
61%
-
Number of buys
-
52
-
Number of sells
-
-69
-
Price
-
$0.7179
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2022
164 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2022.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81,183,875 shares
of 236,234,693 outstanding shares and own 34% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (14,402,988 shares), BlackRock Inc. (13,960,995 shares), STATE STREET CORP (11,488,224 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), JPMORGAN CHASE & CO (4,258,011 shares), GEODE CAPITAL MANAGEMENT, LLC (3,152,758 shares), DIMENSIONAL FUND ADVISORS LP (2,666,861 shares), MILLENNIUM MANAGEMENT LLC (2,631,814 shares), FEDERATED HERMES, INC. (2,030,015 shares), and Orchard Capital Managment, LLC (1,762,731 shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.